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Edited by Angel NebredaAbstract To better understand the outcome of the interaction
between TNF-related apoptosis-inducing factor (TRAIL) and tu-
mor cells, we studied TRAIL-resistant melanoma cells resulting
from prolonged exposure to TRAIL and found that they had
higher proliferative activity than the parental cells both in vitro
and in vivo. This was associated with reduced p53 and p21
expression and increased activation of Erk1/2 and Akt. Acceler-
ated proliferation was not due to TRAIL-mediated signaling but
appeared to be the result of selection of previously existing, char-
acteristically distinct cells. Moreover, responses of p53 to stim-
ulation in the TRAIL-resistant cells appeared to be impaired.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Treatment of melanoma once it has spread beyond the skin
remains unsatisfactory. This is thought to be attributable to
development of resistance of melanoma cells to apoptosis
[1,2]. We have previously shown that a TNF family member,
TNF-related apoptosis-inducing ligand (TRAIL), induces
apoptosis in approximately two-thirds of melanoma cell lines
[3]. This has shed light on treatment of melanoma using strat-
egies based on TRAIL-induced apoptosis. The potential signif-
icance of TRAIL as an anti-cancer agent has been supported
by studies in animal models showing selective toxicity to hu-
man tumor xenografts but not normal tissues [4–6].
Heterogeneous sensitivity of tumor cells to TRAIL-induced
apoptosis, however, may lead to persistent growth of TRAIL-
resistant cells, and limit successful treatment of melanoma by
TRAIL. Given that T lymphocytes and monocytes from mela-
noma patients express TRAIL on their surface [7], it is possible
that melanoma cells may undergo selection by TRAIL in vivo
leading to outgrowth of TRAIL-resistant cells. This isAbbreviations: TRAIL, TNF-related apoptosis-inducing ligand;
TRAIL-Rs, TRAIL receptors; PI, propidium iodide; SBHA, suberic
bishydroxamate; CDDP, cisplatin
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doi:10.1016/j.febslet.2005.02.041supported by the observation that fresh isolates of melanoma
are largely resistant to TRAIL-induced apoptosis [8]. It is there-
fore important to understand the biologic characteristics of tu-
mor cells that are resistant to TRAIL-induced apoptosis.
In the present study, we have generated TRAIL-resistant
melanoma cells by prolonged exposure to TRAIL in vitro.
We report that the resulting TRAIL-resistant melanoma cells
possess higher proliferative potential than their parental coun-
terparts both in vitro and in xenograft models. This was asso-
ciated with reduced expression levels of p21 and p53 and
increased activation of Erk1/2 and Akt. TRAIL-resistant cells
retained high proliferative potential, low levels of p21 and p53,
and high levels of Erk1/2 and Akt activation even after re-
moval of TRAIL. This suggests that accelerated proliferation
was not due to TRAIL-mediated signaling but was the result
of selection of melanoma cells with abnormal p53 responses
and constitutively active ERK1/2 and Akt signal pathways.2. Materials and methods
2.1. Cell culture and reagents
Human melanoma cell lines Mel-FH and Mel-RM have been de-
scribed previously [3,9]. The cell lines were cultured in DMEM con-
taining 5% FCS (Commonwealth Serum Laboratories, Melbourne,
Australia). Recombinant human TRAIL was supplied by Immunex
(Seattle, WA). The preparation was supplied as a leucine zipper fusion
protein, which required no further cross-linking for maximal activity.
The MAbs against TRAIL-R1 (M217), TRAIL-R2 (M413), TRAIL-
R3 (M430) and TRAIL-R4 (M444) were also supplied by Immunex.
Rabbit Abs against Erk1/2, Akt, phospho-Akt and the mouse Ab
against phospho-Erk1/2 were from Cell Signaling (Beverly, MA).
The MAb against p21 and p27 was purchased from BD PharMingen
(San Diego, CA). The MAb against wide type p53 was from Upstate
Biotechnology (Waltham, MA). The MAPK kinase (MEK) inhibitor,
U0126, was purchased from Promega Corporation (Madison, WI).
The PI3-K inhibitor, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-
4-one (LY294002) was purchased from Calbiochem (Kilsyth, Vic.,
Australia). Suberic bishydroxamate (SBHA) was a kind gift from
Dr. P. Parson (Queensland Institute of Medical Research, Brisbane,
Australia). Cisplatin (CDDP) was supplied by Pharmacia Upjohn
(Sydney, NSW, Australia).2.2. Generation of TRAIL-selected cells
Generation of TRAIL-selected resistant cells was performed as de-
scribed previously [8]. Brieﬂy, Mel-RM and Mel-FH cells were seeded
in 25 cm2 culture ﬂasks, and cultured in DMEM containing TRAIL at
200 ng/ml. The surviving cells were fed every 3 days for 5–6 weeks with
culture medium containing TRAIL (200 ng/ml) until they reached 70–
80% conﬂuence. The resulting cells were then passaged and cultured in
the presence of TRAIL for at least 20 weeks. The resulting cell lines
were designated as Mel-RM.S and Mel-FH.S, respectively.blished by Elsevier B.V. All rights reserved.
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Apoptotic cells were determined by the propidium iodide (PI)
method by ﬂow cytometry as described elsewhere [3,9].
2.4. Flow cytometry
Immunostaining on intact and permeabilized cells was carried out as
described previously [3,9]. Analysis was carried out using a Becton
Dickinson (Mountain View, CA) FACScan ﬂow cytometer.
2.5. Western blot analysis
Methods used were as described previously [3,9]. Brieﬂy, the protein
content of cell extracts was determined by the Bradford assay (Bio-
Rad).
2.6. MTT assays
MTT cell proliferation assays were performed using Vybrant MTT
Cell Proliferation Assay Kit from Molecular Probes (Eugene, UR)
according to the manufacturers instruction with minor modiﬁcation.
Brieﬂy, cells were seeded at 5000/well onto ﬂat-bottomed 96-well cul-
ture plates and allowed to grow 24 h followed by desired treatment.
Cells were then labeled with MTT and resulting formazan was solubi-
lized with DMSO. Absorbance was read in a microplate reader (Bio-
Rad) at 540 nm.
2.7. Colony formation assays
Melanoma cells were seeded in 6-well culture plates at ﬁxed densities
(500 cells/well for Mel-RM and Mel-RM.S and 1000 cells/well for Mel-
FH and Mel-FH.S). TRAIL-selected cells were cultured in the pres-Fig. 1. Prolonged exposure to TRAIL selects TRAIL-resistant mela-
noma cells with decreased TRAIL-R expression. Mel-RM and Mel-
FH cells with or without exposure to TRAIL (200 ng/ml) for at least 20
weeks were subjected to measurement of apoptosis by the PI method
(A), analysis for TRAIL-R1 and -R2 expression on intact cells (cell
surface expression) or permeabilized cells (total protein levels) using
ﬂow cytometry (B). The data shown are means ± S.E. of three
individual experiments.ence of TRAIL. At the end of the assay, cells were ﬁxed with methanol
and stained with crystal violet. Colonies with 50 or more cells were
counted under a phase contrast microscope.
2.8. In vivo animal model
Mel-RM andMel-RM.S cells [2 · 106 cells in 200 ml of PBS contain-
ing 20% Matrigel matrix (BD Bioscience, Mountain View, CA)] were
injected subcutaneously in each ﬂank of female NOD-SCID mice (7
mice/group). Tumor growth was monitored by measurements of tumor
diameters with a sliding caliper 2–3 times a week. The tumor volume
was recorded as the length · width · height.3. Results
3.1. Prolonged exposure to TRAIL selects melanoma cells
resistant to TRAIL-induced apoptosis
Fig. 1A shows that continuous exposure ofMel-FH andMel-
RM cells to TRAIL at 200 ng/ml for 20 weeks results in stable
populations of cells resistant to TRAIL-induced apoptosis.
These cells were able to proliferate and to be passaged in the
presence of TRAIL. We characterized the TRAIL-selected cells
in terms of the expression of TRAIL-receptors (TRAIL-Rs) as
shown in Fig. 1B. The cell surface expression of TRAIL-R2, the
major death receptor that mediates TRAIL-induced apoptosis
in melanoma [3], was markedly decreased in the TRAIL-se-
lected cell lines, and the expression of TRAIL-R1 was also
reduced in Mel-FH.S cells. There was no expression of
TRAIL-R1 in Mel-RM and Mel-RM.S cells. TRAIL-R3 andFig. 2. TRAIL-selected melanoma cells have higher proliferative
potential both in vitro and in vivo. (A) Mel-RM and Mel-FH cells
with or without exposure to TRAIL (200 ng/ml) for at least 20 weeks
were subjected to colony formation assays. The TRAIL-selected cells
and the parental cells were seeded onto six-well plates at a ﬁxed density
in culture medium with or without TRAIL, respectively. The data
shown are representative micrographs of three individual expreiments
(left panel), and the numbers of colonies with 50 or more cells in each
well (means ± S.E. of three individual experiments) (right panel).
(B) The TRAIL-selected cells (Mel-RM.S and Mel-FH.S) and the
parental cells (Mel-RM and Mel-FH) were seeded onto ﬂat-bottomed
96-well plates at a ﬁxed density and cultured in medium with or
without TRAIL, respectively, for 5 days. MTT assays were carried out
on day 1, 3, and 5 after seeding. The data shown are means ± S.E. of
three individual experiments. (C) Growth rates of Mel-RM and Mel-
RM.S xenografts in NOD-SCID mice. The data shown are means ±
S.E. of 14 tumors in seven mice for each cell line.
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and Mel-RM or Mel-FH.S and Mel-RM.S cells. Fig. 1B also
shows that the total protein levels of TRAIL-R1 and TRAIL-
R2 in the selected cells as measured in permeabilized cells were
also reduced, although to a lesser extent.
3.2. TRAIL-selected melanoma cells have higher proliferative
potential than the parental counterparts both in vitro and
in vivo
We examined colony formation activity of the TRAIL-se-
lected cells in comparison with that of the parental cells by
seeding the cells onto six-well culture plates at a ﬁxed density
in culture medium with or without TRAIL, respectively. As
shown in Fig. 2A and B, the TRAIL-selected cells appeared
to be more active in colony formation than the parental cells.
This suggests that the TRAIL-selected cells may have higher
proliferative potential. The latter was conﬁrmed in MTT as-
says as shown in Fig. 2B. The proliferative activity of the
TRAIL-selected cells appeared to be markedly increased in
both Mel-RM.S and Mel-FH.S in comparison with their
parental counterparts.
To further conﬁrm the increased proliferative capacity of the
TRAIL-selected cells, we transplanted Mel-RM and
Mel-RM.S cells subcutaneously into each ﬂank of female
NOD-SCID mice (7 mice/group). As shown in Fig. 2C, whileFig. 3. (A) TRAIL-selected melanoma cells express lower levels of p21 an
TRAIL-selected (Mel-RM.S and Mel-FH.S) melanoma cells were subjected
independent of TRAIL-mediated signaling. Whole cell lysates from Mel-RM
culture medium for 15 days were subjected to Western blot analysis. (C) Eﬀe
parental and TRAIL-selected cells. Whole cell lysates from Mel-RM and M
(5 lg/ml) for 16 h were subjected to Western blot analysis. The data shown
colony formation activity of both the parental and TRAIL-selected cells. Mel
culture medium with SBHA (10 lg/ml) or the vehicle alone (control; distilled
cells in each well of six-well plates (means ± S.E. of three individual experimen
and TRAIL-selected cells. Mel-RM and Mel-RM.S cells seeded onto ﬂat-bott
(10 lg/ml) or the vehicle alone (control; distilled water) for another 4 days
individual experiments.Mel-RM.S xenografts became measurable at 16 days after
transplantation, the onset of Mel-RM xenografts was only de-
tected 24-28 days after transplantation. By day 36 when the
experiment ceased, the mean tumor size of Mel-RM.S trans-
plants was 4.9 times larger than that of Mel-RM transplants
(166.3 mm3vs. 33.8 mm3). This suggests that TRAIL-selected
melanoma cells have higher proliferative potential not only
in vitro, but also in vivo.
3.3. TRAIL-selected melanoma cells expressed low levels of p21
and p53
As shown in Fig. 3A, the expression levels of p21 and p53
were decreased in Mel-FH.S and Mel-RM.S, but the expres-
sion levels of p27 remained unchanged between the parental
and selected cells. To study if the decrease in p21 and p53 re-
sulted from TRAIL-mediated signaling, we withdrew TRAIL
from the culture medium and found that the levels at 15 days
after removal of TRAIL remained as low as those seen in the
presence of TRAIL (Fig. 3B). Similarly, addition of an antag-
onistic antibody against TRAIL, M180, into the culture med-
ium containing TRAIL did not change the levels of expression
of p21 and p53 (data not shown).
To conﬁrm the role of decreased expression of p21 and p53
in the increased proliferative activity of TRAIL-selected cells,
we treated Mel-FH.S and Mel-RM.S with the histoned p53. Whole cell lysates from parental (Mel-RM and Mel-FH) and
to Western blot analysis. (B) Decreased expression of p21 and p53 is
and Mel-RM.S cells with or without removal of TRAIL from the
cts of SBHA and CDDP on the expression levels of p21 and p53 in the
el-RM.S with or without treatment with SBHA (10 lg/ml) or CDDP
are representative of two individual experiments. (D) SBHA inhibited
-RM and Mel-RM.S cells were subjected to colony formation assays in
water). The data shown are the numbers of colonies with 50 or more
ts). (E) SBHA inhibited the proliferative potential of both the parental
omed 96-well plates at a ﬁxed density for 24 h were treated with SBHA
followed by MTT assays. The data shown are means ± S.E. of three
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DNA damaging agent CDDP to upregulate p53 [12]. As
shown in Fig. 3C, SBHA markedly upregulated p21 in the
TRAIL-selected cells as it did in the parental cells without
changing the expression levels of p53. This was associated with
a decrease in cellular proliferation (Fig. 3D). Unexpectedly,
CDDP failed to signiﬁcantly up-regulate p53 in the TRAIL-se-
lected cells, although it did in the parental cells (Fig. 3C). This
suggests that the response of p53 to DNA damage in the
TRAIL-selected cells was impaired.
3.4. Increased activation of Erk1/2 and Akt plays a role in
sustaining the high proliferative potential of TRAIL-
selected cells
As shown in Fig. 4A, while phosphorylation of both Erk1/2
and Akt was detected at low levels in the parental cells, it wasFig. 4. (A) Increased activation of ERK1/2 and Akt in TRAIL-
selected melanoma cells. Whole cell lysates from parental (Mel-RM
and Mel-FH) and TRAIL-selected (Mel-RM.S and Mel-FH.S) mela-
noma cells were subjected to Western blot analysis. (B) Increased
activation of ERK1/2 and Akt is independent of TRAIL-mediated
signaling. Whole cell lysates from Mel-RM and Mel-RM.S cells with
or without removal of TRAIL from the culture medium for 15 days
were subjected to Western blot analysis. (C) Inhibition of ERK1/2 or
Akt inhibited increased colony formation activity of the TRAIL-
selected cells. Mel-RM and Mel-RM.S cells were subjected to colony
formation assays in culture medium with U0126 (20 lM) or LY294002
(20 lM), or the vehicle alone (control; DMSO). The data shown are
the numbers of colonies with 50 or more cells in each well of six-well
plates (means ± S.E. of three individual experiments). (D) Inhibition of
ERK1/2 or Akt removed the proliferative advantage of the TRAIL-
selected cells. Mel-RM and Mel-RM.S cells seeded onto ﬂat-bottomed
96-well plates at a ﬁxed density for 24 h were treated with either U0126
(20 lM) or LY294002 (20 lM), or the vehicle alone (control; DMSO)
for another 4 days followed by MTT assays. The data shown are
means ± S.E. of three individual experiments.clearly increased in the TRAIL-selected cells. There was no
apparent diﬀerence in the expression levels of the native ki-
nases. Fig. 4B shows that Erk1/2 and Akt activation in the
TRAIL-selected cells remained relatively high even after re-
moval of TRAIL from the culture for 15 days. Fig. 4C shows
that the addition of either U0126 or LY294002 in the culture
medium markedly inhibited cellular proliferation in both the
parental and the TRAIL-selected cells to the same degree.4. Discussion
Resistance of tumor cells to TRAIL poses a potential limita-
tion to its use in treatment. To understand the basis for the
resistance of melanoma cells that had been selected by pro-
longed exposure to TRAIL in vitro, we examined their growth
characteristics and the signal pathways that may be involved.
Our results show that the TRAIL-resistant cells had higher
proliferative potential than their parental counterparts both
in vitro and in vivo. This was associated with decreased expres-
sion levels of two major cell cycle regulators, p21 and p53, and
increased activation of Erk1/2 and Akt.
In addition to inducing apoptosis, TRAIL can activate a
number of survival signaling pathways in melanoma cells such
as those mediated by the transcription factor NF-jB and the
mitogen activated protein kinase ERK1/2 [10,13], both of
which play an important role in regulation of cellular prolifer-
ation. TRAIL-induced activation of NF-jB was shown to
mediate proliferation of endothelial cells and more recently
was reported to induce proliferation of a variant of human Jur-
kat T lymphocytes that lacked caspase-8 expression [14,15]. It
seems unlikely, however, that the increased proliferation of
TRAIL-selected cells resulted from TRAIL-mediated signaling
as only a small proportion of TRAIL-selected cells expressed
TRAIL receptors on their surface, which indicates that
TRAIL-mediated signaling was unlikely. TRAIL-selected cells
also retained high proliferative potential even after removal of
TRAIL from culture medium for 2 weeks in vitro and in vivo
as xenografts in NOD-SCID mice.
ERK1/2 is known to be constitutively activated to varying
degrees in melanoma cell lines and constitutive activation of
Akt has also been reported in the majority of melanoma cell
lines [9,16]. In the present study, we showed that TRAIL-se-
lected melanoma cells had higher levels of activation of
ERK1/2 and Akt. This played a critical role in sustaining high-
er proliferative potential of the cells. TRAIL is believed to pro-
mote the survival and proliferation of primary human vascular
endothelial cells by activating the Akt and ERK1/2 pathways
[14]. We found however that increased activation of ERK1/2
and Akt in TRAIL-selected cells did not appear to be due to
TRAIL-mediated signaling. This suggests that prolonged
exposure to TRAIL resulted in selection of melanoma cells
with constitutive activation of ERK1/2 and Akt.
Accelerated proliferation of the TRAIL-selected cells was
associated with decreased levels of p21 and p53. The role of
the former was supported by using the histone deacetylase
inhibitor SBHA to restore the expression levels, which reversed
the high proliferative potential of the TRAIL-selected cells
[10]. SBHA-mediated up-regulation of p21 in melanoma cells
appeared to be p53-independent as reported for other histone
deacetylase inhibitors in that SBHA did aﬀect the expression
levels of p53 [17]. Unexpectedly, while the DNA-damaging
1944 J.J. Wu et al. / FEBS Letters 579 (2005) 1940–1944agent CDDP upregulated the expression levels of p53 in the
parental cells, it had only a minor eﬀect on the TRAIL-selected
cells. The basis for the impaired response of p53 to DNA dam-
age is not known but abnormality in the p53 response may be a
key factor in the increased proliferation of TRAIL selected
cells.
The exact mechanism(s) by which TRAIL-R1 and -R2
expression was suppressed in TRAIL-selected melanoma cells
remains unknown. It was recently reported that down-regula-
tion of cell surface TRAIL death receptor expression in
TRAIL-selected colon adenocarcinoma cells was due to deﬁ-
cient transport of the proteins to the cell surface [18]. Our cur-
rent results, however, suggest that mechanism(s) upstream of
protein synthesis may also be involved as the total protein lev-
els of TRAIL-R1 and -R2 in the TRAIL-selected melanoma
cells also appeared to be decreased. This may be due to de-
creased levels of p53 expression in that both TRAIL-R1 and
TRAIL-R2 are known to be transcriptionally regulated by
p53 [19,20]. Activation of NF-jB is known to be an important
factor in regulation of apoptosis and cellular proliferation, but
is unlikely to play a signiﬁcant role in the increased prolifera-
tion of the TRAIL-selected melanoma cells. This is because the
levels of activation of NF-jB was lower in both of the selected
cell lines, and TRAIL did not induce any increase in activation
of NF-jB in the TRAIL-selected cells as it did in the parental
cells (data not shown). The cause of lower NF-jB activation in
the TRAIL-selected cells remains to be studied.
In conclusion, the current study demonstrated that pro-
longed exposure to TRAIL resulted in melanoma cells that
were not only resistant to TRAIL-induced apoptosis but also
had higher proliferative potential both in vitro and in vivo that
was associated with low p21 expression and activation of
ERK1/2 and Akt pathways. This was not due to TRAIL-
mediated signaling but appeared to be due to selection of cells
with these characteristics. These ﬁndings appear to have
important implications for use of TRAIL in treatment of can-
cer in that cells that survive TRAIL-induced apoptosis may
have increased proliferative potential. It is also possible that
immunotherapies that increase TRAIL expression in immune
eﬀector cells may result in a similar selection of TRAIL-resis-
tant cells with increased proliferative activity.
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